VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

Verona Pharma Executive Compensation (FY24)

VRNA · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024
◇
David Zaccardelli
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Verona Pharma

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 4, 2026Latest filing (DEF 14A): March 18, 2025
1 filing cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Verona Pharma brief$500Get the executive brief
Velarion Intel, one year, every company
166 figures on this page, cited to the filing that reported them. See the citations

More on Verona Pharma

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — David Zaccardelli: $6,597,473 → $19,456,473 (194.9% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Verona Pharma's chief executive and what were they paid?
David Zaccardelli, President and Chief Executive Officer, received $19,456,473 in total compensation for fiscal 2024. Zaccardelli's total moved 194.9% higher from the $6,597,473 reported for fiscal 2023.
Which companies are in Verona Pharma's peer group?
Companies named in the disclosed peer group include Agios Pharmaceuticals, Akero Therapeutics, Aurinia Pharmaceuticals, Axsome Therapeutics and BioCryst Pharmaceuticals, among others.
What is Verona Pharma's chief executive pay ratio?
For fiscal 2024, the company reported a chief executive pay ratio of 44:1, against median employee compensation of $444,444.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Zaccardelli
President and Chief Executive Officer
◇—◇—◇—◇◇
Mark Hahn
Chief Financial Officer
◇—◇—◇—◇◇
Kathleen Rickard
Chief Medical Officer
◇—◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Zaccardelli
President and Chief Executive Officer
◇—◇—◇—◇◇
Mark Hahn
Chief Financial Officer
◇—◇—◇—◇◇
Kathleen Rickard
Chief Medical Officer
◇—◇—◇——◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Zaccardelli
President and Chief Executive Officer
◇—◇—◇—◇◇
Mark Hahn
Chief Financial Officer
◇—◇—◇—◇◇
Andrew Fisher
General Counsel
◇—◇◇◇—◇◇
Kathleen Rickard
Chief Medical Officer
◇—◇—◇——◇
Claire Poll
Former General Counsel
Departed during or after this year
◇——————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Andrew FisherRSU◇——◇——◇
Andrew FisherPSU◇◇◇—◇—◇
Andrew FisherOPTION◇——◇—◇◇
David ZaccardelliRSU◇——◇——◇
David ZaccardelliPSU◇◇◇—◇—◇
Kathleen RickardRSU◇——◇——◇
Kathleen RickardPSU◇◇◇—◇—◇
Mark W. HahnRSU◇——◇——◇
Mark W. HahnPSU◇◇◇—◇—◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Andrew FisherOption◇—◇March 31, 2034
PSU◇◇——
RSU◇◇——
Mark HahnPSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
David ZaccardelliPSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Kathleen RickardPSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Ebsworth, Ph.D
Board chair
◇—◇———◇
Vikas Sinha
◇—◇———◇
Christina Ackermann
◇—◇———◇
Kenneth Cunningham, M.D
◇—◇———◇
James Brady
◇—◇———◇
Lisa Deschamps
◇—◇———◇
Mahendra Shah, Ph.D
◇—◇———◇
Anders Ullman, M.D., Ph.D
◇—◇———◇
Martin Edwards, M.D
◇—◇———◇
Michael Austwick
◇—◇———◇
Rishi Gupta
◇—————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Agios Pharmaceuticals AGIO
  • Akero Therapeutics AKRO
  • Aurinia Pharmaceuticals AUPH
  • Axsome Therapeutics AXSM
  • BioCryst Pharmaceuticals BCRX
  • Heron Therapeutics HRTX
  • Immunocore Holdings IMCR
  • Madrigal Pharmaceuticals MDGL
  • Phathom Pharmaceuticals PHAT
  • Rhythm Pharmaceuticals RYTM
  • SpringWorks Therapeutics SWTX
  • Tarsus Pharmaceuticals TARS
  • TG Therapeutics TGTX
  • Viridian Therapeutics VRDN
  • Xenon Pharmaceuticals XENE

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- David Zaccardelli (President and Chief Executive Officer), FY2024 total compensation $19,456,473 (base salary $873,015) [exec_comp, SEC accession 0001104659-25-025050, filed 2025-03-18]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Verona Pharma files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Verona Pharma disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Verona Pharma sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Verona Pharma's disclosed peer group is defensible, who names Verona Pharma back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
166 figures on this page, cited to the filing that reported them.
166 cited to the filing

Documents cited

  1. 0001104659-25-025050
    CEO Pay Ratio · DIRECTOR COMPENSATION · EXECUTIVE COMPENSATION TABLES
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Verona Pharma executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/VRNA (accessed 2026).
Short form: data: Velarion

The paid brief for Verona Pharma

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Verona Pharma and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Verona Pharma discloses

The companies named in VRNA's own disclosed peer group.

Agios PharmaceuticalsAkero TherapeuticsAurinia PharmaceuticalsAxsome TherapeuticsBioCryst PharmaceuticalsHeron TherapeuticsImmunocore HoldingsMadrigal PharmaceuticalsPhathom PharmaceuticalsRhythm PharmaceuticalsSpringWorks TherapeuticsTarsus PharmaceuticalsTG TherapeuticsViridian TherapeuticsXenon Pharmaceuticals

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy